# HOVON

Source: https://onco.cc/companies/hovon/  
OnCo record `hovon` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

The Dutch-Belgian adult haematology trials group, one of Europe's largest engines of leukaemia, myeloma and lymphoma phase 3 trials.

## Summary

Founded in 1985 and coordinated from Rotterdam, HOVON runs trials across the Netherlands, Belgium and partner countries, often jointly with the Swiss SAKK and the German and Nordic groups. Its AML trials defined intensive induction, consolidation and transplant strategies in adults and the elderly, HOVON-65/GMMG-HD4 established bortezomib in myeloma induction and maintenance, and HOVON lymphoma and CLL studies contribute to European standards. HOVON participates in the European Myeloma Network trials and runs a national data centre and biobank. Most Dutch adults with acute leukaemia are treated within or according to a HOVON protocol.

## Fields

- Kind: Company
- Last checked: 2026-09-09
- Also known as: Haemato Oncology Foundation for Adults in the Netherlands; Stichting Hemato-Oncologie voor Volwassenen Nederland
- Tags: cooperative-group
- HQ: Rotterdam
- Type: cooperative-group
- Website: https://hovon.nl

## Notes

- AML trials (with SAKK)
- Myeloma (HOVON-65/GMMG-HD4, EMN trials)
- Lymphoma and CLL
- National haematology data centre

## Sources

- HOVON: https://hovon.nl
- Trials: https://hovon.nl/en/trials

## Connected records

- trials: [PERSEUS](https://onco.cc/trials/perseus/), [Prevention of Anthracycline-Induced Cardiac Dysfunction With Dexrazoxane in Patients With Diffuse Large-B Cell Lymphoma](https://onco.cc/trials/nct06220032/)
- drugs: [Venetoclax](https://onco.cc/drugs/venetoclax/)
- cancers: [Acute lymphoblastic leukaemia](https://onco.cc/cancers/all-leukemia/), [Acute myeloid leukaemia](https://onco.cc/cancers/aml/), [Chronic lymphocytic leukaemia](https://onco.cc/cancers/cll/), [Diffuse large B-cell lymphoma](https://onco.cc/cancers/dlbcl/), [Hodgkin lymphoma](https://onco.cc/cancers/hodgkin-lymphoma/), [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/)
- technologies: [MRD / molecular residual disease testing](https://onco.cc/technologies/mrd-testing/)
- companies: [German Lymphoma Alliance](https://onco.cc/companies/german-lymphoma-alliance/), [GIMEMA](https://onco.cc/companies/gimema/), [International Extranodal Lymphoma Study Group](https://onco.cc/companies/ielsg/), [Nordic Lymphoma Group](https://onco.cc/companies/nordic-lymphoma-group/)
- institutions: [European Hematology Association](https://onco.cc/institutions/eha/), [KWF Dutch Cancer Society](https://onco.cc/institutions/kwf/), [Netherlands Cancer Institute (NKI-AvL)](https://onco.cc/institutions/nki/)
- terms: [Minimal / molecular residual disease (MRD)](https://onco.cc/terms/mrd/)
- people: [Marc H.G.P. Raaijmakers](https://onco.cc/people/marc-raaijmakers/), [Nicolaas P.M. Schaap](https://onco.cc/people/nicolaas-schaap/), [Pieter Sonneveld](https://onco.cc/people/pieter-sonneveld/)

---
JSON: https://onco.cc/api/v1/entities/hovon.json